Catalyst Pharmaceuticals Inc
CPRX24.350USD
-0.100-0.41%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
3.00BCap. mercado
13.59P/E TTM
Más Datos de Catalyst Pharmaceuticals Inc Compañía
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Información de Catalyst Pharmaceuticals Inc
Símbolo de cotizaciónCPRX
Nombre de la empresaCatalyst Pharmaceuticals Inc
Fecha de salida a bolsaNov 08, 2006
Director ejecutivoDaly (Richard J)
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
Dirección355 Alhambra Circle
CiudadCORAL GABLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33134
Teléfono13055292522
Sitio Webhttps://catalystpharma.com/
Símbolo de cotizaciónCPRX
Fecha de salida a bolsaNov 08, 2006
Director ejecutivoDaly (Richard J)
Ejecutivos de Catalyst Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
50.51K
+11.44%
Mr. Jeffrey Del Carmen
Mr. Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.51K
+140.01%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
9.11K
+18.37%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.15M
-3.07%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.08M
+1.11%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
497.44K
+0.28%
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
381.98K
+0.37%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
238.93K
+5.35%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
238.46K
+1.83%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Otro
67.32%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.98%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
Deerfield Management Company, L.P.
4.05%
McEnany (Patrick James)
3.38%
Otro
67.32%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
44.17%
Investment Advisor/Hedge Fund
27.08%
Hedge Fund
11.03%
Individual Investor
6.07%
Research Firm
2.77%
Pension Fund
1.37%
Bank and Trust
0.51%
Family Office
0.14%
Sovereign Wealth Fund
0.07%
Otro
6.79%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
701
106.95M
89.84%
+15.25K
2025Q3
712
106.95M
90.45%
+1.69M
2025Q2
692
104.76M
87.33%
+3.07M
2025Q1
677
101.32M
86.64%
-4.35M
2024Q4
648
100.17M
86.81%
+1.55M
2024Q3
616
97.42M
88.20%
-1.98M
2024Q2
584
98.72M
96.71%
+772.63K
2024Q1
576
98.03M
86.91%
-4.54M
2023Q4
556
86.46M
95.57%
+3.15M
2023Q3
535
83.30M
96.60%
-1.62M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
16.29M
13.31%
-124.58K
-0.76%
Jun 30, 2025
The Vanguard Group, Inc.
8.74M
7.14%
+268.10K
+3.16%
Jun 30, 2025
State Street Investment Management (US)
5.48M
4.48%
-52.05K
-0.94%
Jun 30, 2025
Deerfield Management Company, L.P.
2.88M
2.35%
-542.67K
-15.86%
Jun 30, 2025
McEnany (Patrick James)
4.28M
3.5%
-200.00K
-4.46%
Jun 09, 2025
Renaissance Technologies LLC
3.25M
2.66%
+295.20K
+9.99%
Jun 30, 2025
Fundsmith LLP
2.71M
2.21%
+557.81K
+25.93%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.87M
2.34%
+101.13K
+3.66%
Jun 30, 2025
American Century Investment Management, Inc.
1.76M
1.44%
+1.23M
+233.86%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.91M
1.56%
-279.90K
-12.80%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.37%
Invesco Biotechnology & Genome ETF
3.14%
Invesco S&P SmallCap Health Care ETF
1.5%
Janus Henderson Small Cap Growth Alpha ETF
1.46%
Invesco S&P SmallCap 600 GARP ETF
1.39%
ETC 6 Meridian Small Cap Equity ETF
1.27%
VictoryShares Small Cap Free Cash Flow ETF
1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
1.1%
First Trust Small Cap US Equity Select ETF
1.07%
Cambria Value and Momentum ETF
0.97%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.37%
Invesco Biotechnology & Genome ETF
Proporción3.14%
Invesco S&P SmallCap Health Care ETF
Proporción1.5%
Janus Henderson Small Cap Growth Alpha ETF
Proporción1.46%
Invesco S&P SmallCap 600 GARP ETF
Proporción1.39%
ETC 6 Meridian Small Cap Equity ETF
Proporción1.27%
VictoryShares Small Cap Free Cash Flow ETF
Proporción1.15%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción1.1%
First Trust Small Cap US Equity Select ETF
Proporción1.07%
Cambria Value and Momentum ETF
Proporción0.97%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Catalyst Pharmaceuticals Inc?
Los cinco principales accionistas de Catalyst Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A. posee 16.29M acciones, lo que representa el 13.31% del total de acciones.
The Vanguard Group, Inc. posee 8.74M acciones, lo que representa el 7.14% del total de acciones.
State Street Investment Management (US) posee 5.48M acciones, lo que representa el 4.48% del total de acciones.
Deerfield Management Company, L.P. posee 2.88M acciones, lo que representa el 2.35% del total de acciones.
McEnany (Patrick James) posee 4.28M acciones, lo que representa el 3.50% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 16.29M acciones, lo que representa el 13.31% del total de acciones.
The Vanguard Group, Inc. posee 8.74M acciones, lo que representa el 7.14% del total de acciones.
State Street Investment Management (US) posee 5.48M acciones, lo que representa el 4.48% del total de acciones.
Deerfield Management Company, L.P. posee 2.88M acciones, lo que representa el 2.35% del total de acciones.
McEnany (Patrick James) posee 4.28M acciones, lo que representa el 3.50% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Catalyst Pharmaceuticals Inc?
Los tres principales tipos de accionista de Catalyst Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Catalyst Pharmaceuticals Inc (CPRX)?
A fecha de 2025Q4, 701 instituciones poseen acciones de Catalyst Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 106.95M, lo que representa el 89.84% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.61%.
¿Cuál es la mayor fuente de ganancias de Catalyst Pharmaceuticals Inc?
El --, el segmento empresarial -- generó la ganancia más alta para Catalyst Pharmaceuticals Inc, ascendiendo a -- y representando el --% de la ganancia total.
